BRAF inhibitors: resistance and the promise of combination treatments for melanoma

Identification of mutations in the gene encoding the serine/threonine-protein kinase, BRAF, and constitutive activation of the mitogen-activated protein kinase (MAPK) pathway in around 50% of malignant melanomas have led to the development and regulatory approval of targeted pathway inhibitor drugs....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Griffin, Merope, Scotto, Daniele, Josephs, Debra H., Mele, Silvia, Crescioli, Silvia, Bax, Heather J., Pellizzari, Giulia, Wynne, Matthew D., Nakamura, Mano, Hoffmann, Ricarda M., Ilieva, Kristina M., Cheung, Anthony, Spicer, James F., Papa, Sophie, Lacy, Katie E., Karagiannis, Sophia N.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5652848/
https://ncbi.nlm.nih.gov/pubmed/29100459
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.19836
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados